Related Experiment Videos
Prospective study of FK506 side effects: anxiety or akathisia?
A F DiMartini1, P T Trzepacz, S R Daviss
1Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, PA 15213, USA.
Abstract:
FK506 is a macrolide immunosuppressant agent used in solid organ and bone marrow transplantation and for autoimmune disorders. FK506 is reported to have a number of neuropsychiatric side effects, including anxiety and tremor. Because FK506 was implicated in causing akathisia in a case report, we did a prospective, cross-sectional study of 25 renal transplant recipients to determine whether akathisia occurred and/or had a relationship to FK506 plasma levels. The Symptom Checklist-90-R, Hamilton Anxiety (HAM-A), and Akathisia Rating (ARS) scales were administered. Higher FK506 plasma levels correlated with higher HAM-A scores. ARS scores did not correlate with FK506 plasma levels; however, when FK506 plasma levels were divided into "high" (> or = 0.9 ng/mL) and "low" (< 0.9 ng/mL) groups, total ARS and HAM-A scores were significantly higher in the "high" group. We discuss implications of these findings as well as management.
Insights
FK506, an immunosuppressant, may cause anxiety and akathisia in renal transplant patients. Higher FK506 levels correlated with increased anxiety and akathisia symptoms.
Area of Science:
- Pharmacology
- Nephrology
- Psychiatry
Background:
- FK506 (tacrolimus) is a crucial immunosuppressant for organ transplant recipients.
- Neuropsychiatric side effects, including anxiety and tremor, are known FK506 complications.
- A case report suggested FK506 may induce akathisia, necessitating further investigation.
Purpose of the Study:
- To prospectively assess the occurrence of akathisia in renal transplant recipients.
- To determine the relationship between FK506 plasma levels and akathisia.
- To evaluate the association between FK506 levels and anxiety symptoms.
Main Methods:
- A cross-sectional study involving 25 renal transplant recipients.
- Administration of Symptom Checklist-90-R, Hamilton Anxiety (HAM-A), and Akathisia Rating (ARS) scales.
- Correlation analysis between FK506 plasma levels and psychometric scale scores.
Main Results:
- Higher FK506 plasma levels showed a correlation with elevated HAM-A scores.
- While ARS scores did not directly correlate with FK506 levels, the 'high' FK506 group (> or = 0.9 ng/mL) exhibited significantly higher total ARS and HAM-A scores.
- This suggests a potential threshold effect of FK506 levels on neuropsychiatric symptoms.
Conclusions:
- FK506 plasma levels may be associated with increased anxiety and akathisia in renal transplant recipients.
- Monitoring FK506 levels and assessing for neuropsychiatric side effects is important for patient management.
- Further research is warranted to elucidate the mechanisms and clinical implications.